One of the things that I’ve heard repeatedly over the last year is that many researchers want a better biomarker of response for checkpoint therapies than PD-L1 expression by IHC.
Indeed, we could expand that statement more broadly to say that there’s a real need for a better predictive biomarker of response to any immunotherapy, since there are more approaches out there now and not just checkpoint blockade. Plus combinations are evolving, complicating things further.
Fair enough, but what’s happening in this space? Anything, Bueller?
We’ve covered a few emerging ideas in the past, although they were based on retrospective analysis – usually with a small N – and remain to be validated in prospective clinical trials.
There’s quite a few groups now much more active in research in this space, from academia to industry. This is a good time to take stock and look at some of the emerging technologies that might be making a splash later if the data pans out.
To learn more insights on this intriguing topic, subscribers can log-in or you can click to gain access to BSB Premium Content.
The audience of Biotech Strategy Blog is a broad “church” (no pun intended) of professionals associated with cancer drug development.
Bridge of Sighs, Oxford
Some readers with a research focus noticed I was in Oxford recently then contacted me to ask what scientific papers I was reading and catching up on over the lazy summer months?
This got me thinking as I was vividly reminded of my days as a PhD student at King’s College London, where the department would regularly meet to discuss key papers and recent research.
If your work has a narrow focus, and that applies to industry too, it’s sometimes difficult to see what’s on the horizon or be stimulated by ideas outside your immediate field, yet cross-fertilisation is an important pillar of learning. That’s one of the advantages of BSB, we cover a wide range of topics, at varying levels of complexity.
Welcome to the BSB Journal Club!
In this inaugural post, I’ve selected several recently published cancer immunotherapy papers that caught my attention, also a couple of books for your summer reading.
In case you worry that the science is above your ‘pay grade,’ for each I’ve written a brief summary and highlighted what data means from a commercial/new product development persepctive. You are of course most welcome to agree/disagree and reach your own conclusions… I hope it will stimulate your thinking.
Science often moves forward and develops as people make connections from a broader perspective. I’m planning on running the “Journal Club” as a monthly ad hoc post to dovetail with the Reader Q&A Mailbag.
Subscribers can login or you can purchase access.